Market News AIOpen the app

Guggenheim increased its price target for Helus Pharma from $45.00 to $49.00.

OpinionRead the original at moomoo.com
Good for HELP

Guggenheim raised its target, signaling a more favorable view of Helus Pharma shares. The report gives no new company results, so the support comes only from the analyst's opinion.

HELP · Helus Pharma

AI read · Good for HELP

The AI's read

A higher target means Guggenheim sees more potential in Helus Pharma shares. The report adds no new trial, sales, or profit results, so this signal rests on one firm's view.

Get alerts for HELP

Follow Helus Pharma (HELP) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for HELP
Free on the App Store and Google Play, or on the web.